Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [903]

ECCO 15 - ESMO 34 Conference

Prof José Baselga - President of ESMO

ECCO 15 - ESMO 34 Conference ( Prof José Baselga - President of ESMO )

Targeted agents in the treatment of advanced NSCLC

Prof Johan Vansteenkiste - Leuven University Hospital, Belgium

Targeted agents in the treatment of advanced NSCLC ( Prof Johan Vansteenkiste - Leuven University Hospital, Belgium )

ECCO 15 - ESMO 34 News 23rd September 2009

Prof Gordon McVie - ecancer Managing Editor

ECCO 15 - ESMO 34 News 23rd September 2009 ( Prof Gordon McVie - ecancer Managing Editor )

ECCO 15 - ESMO 34 News 22nd September 2009

Prof Gordon McVie - ecancer Managing Editor

ECCO 15 - ESMO 34 News 22nd September 2009 ( Prof Gordon McVie - ecancer Managing Editor )

ECCO 15 - ESMO 34 News 20-21 September, 2009

Prof Gordon McVie - ecancer Managing Editor

ECCO 15 - ESMO 34 News 20-21 September, 2009 ( Prof Gordon McVie - ecancer Managing Editor )

ECCO 15 - ESMO 34 Chairs: Why join us in Berlin?

Why attend ECCO 15 - ESMO 34?

ECCO 15 - ESMO 34 Chairs: Why join us in Berlin? ( Why attend ECCO 15 - ESMO 34? )

The Oncopolicy Roundtable: ECCO's President and special guests highlight key...

ECCO 15 - ESMO 34

The Oncopolicy Roundtable: ECCO's President and special guests highlight key issues ( ECCO 15 - ESMO 34 )

Selecting appropriate first line lung cancer therapy

Dr Paul Bunn - University of Colorado, Denver, USA

Selecting appropriate first line lung cancer therapy ( Dr Paul Bunn - University of Colorado, Denver, USA )

Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo

Dr Pierre Fouret - Institut Gustave Roussy, France

Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo ( Dr Pierre Fouret - Institut Gustave Roussy, France )

Targeting death receptors in chemo-resistant cancer cells

Prof Patrick Johnston - Queen's University Belfast, UK

Targeting death receptors in chemo-resistant cancer cells ( Prof Patrick Johnston - Queen's University Belfast, UK )

ASCO: Pemetrexed extends survival as maintenance therapy

Dr. Chandra P. Belani - Penn State Cancer Institute, Hershey, Pennsylvania, USA

ASCO: Pemetrexed extends survival as maintenance therapy ( Dr. Chandra P. Belani - Penn State Cancer Institute, Hershey, Pennsylvania, USA )

ASCO: Lung cancer screening by low-dose computed tomography results in high...

Dr. Jennifer M. Croswell - National Institutes of Health, Bethesda, Maryland...

ASCO: Lung cancer screening by low-dose computed tomography results in high rate of false positives ( Dr. Jennifer M. Croswell - National Institutes of Health, Bethesda, Maryland, USA )

More from ecancer